Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 310 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... March 25, 2021 Regular Exercise May Help Guard Breast Cancer Patients From Chemo Brain August 20, 2021 Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto August 20, 2020 Load more HOT NEWS Closing the gap: How new screening interventions could reduce inequalities in... ESMO 2024 Press Conference Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... Study Reinforces Treatment Idea for Cancer with Microsatellite Instability
